Sangamo Therapeutics, Inc. (SGMO) News

Sangamo Therapeutics, Inc. (SGMO): $0.61

0.04 (-5.39%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add SGMO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#292 of 362

in industry

Filter SGMO News Items

SGMO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SGMO News From Around the Web

Below are the latest news stories about SANGAMO THERAPEUTICS INC that investors may wish to consider to help them evaluate SGMO as an investment opportunity.

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | November 21, 2023

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and thank you for standing by. Welcome to the Sangamo Third Quarter 2023 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised […]

Yahoo | November 3, 2023

Sangamo to cut jobs again with planned business overhaul

The gene therapy company will move headquarters and reduce its workforce by 40%, while seeking partners for its Fabry and cell therapy research.

Yahoo | November 2, 2023

Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update

Company focuses on neurology-focused genomic medicine, announces restructuring and workforce reduction

Yahoo | November 1, 2023

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

BRISBANE, Calif., November 01, 2023--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Yahoo | November 1, 2023

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 26, 2023

Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

BRISBANE, Calif., October 25, 2023--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

Yahoo | October 25, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

BRISBANE, Calif., October 24, 2023--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT

Yahoo | October 24, 2023

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

BRISBANE, Calif., September 20, 2023--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Yahoo | September 20, 2023

Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year

Key Insights Significantly high institutional ownership implies Sangamo Therapeutics' stock price is sensitive to their...

Yahoo | September 4, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!